Cancer stem cells and cancer resistance to therapy;Macierzyste komórki nowotworowe, a oporność nowotworów na terapiȩ

Nowotwory

Volumn 59, Issue 6, 2009, Pages 456-463

  Statkiewicz, Małgorzata ^a   Małecki, Maciej ^a,b  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer stem cells; Cancerogenesis; Chemoresistance

Indexed keywords

ABC TRANSPORTER; BIOLOGICAL MARKER;

ANTIANGIOGENIC THERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; REVIEW; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

EID: 77249110882     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-82.
2. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006; 17: 1620-4.
3. Witoń M. Laboratorium Medyczne 2007; 7-8: 51-2.
4. Gil J, Stembalska A, Pesz K, Sa̧siadek M. Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 2008; 49: 193-9.
5. Gao J-X. Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med 2008; 12: 67-96.
6. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-54.
7. Koestenbauer S, Zech NH, Juch H i wsp. Embryonic stem cells: similarities and differences between human and murine embryonic stem cells. Am J Reprod Immunol 2006; 55: 169-80.
8. Kondo M, Wagers AJ, Manz MG i wsp. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759-806.
9. Moore KA, Lemischka IR. Stem cells and their niches. Science 2006; 311: 1880-5.
10. Zhang J, Niu C, Ye L i wsp. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-41.
11. Ponnusamy MP, Batra SK. Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 2008; 1: 1-9.
12. Lapidot T, Sirard C, Vormoor J i wsp. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
13. Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol 2006; 2: 723-31.
14. Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
15. Reya T, Morrison SJ, Clarke MF i wsp. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
16. Seaberg RM, van der KD. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci 2003; 26: 125-31.
17. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-20.
18. Brown MD, Gilmore PE, Hart CA i wsp. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007; 67: 1384-96.
19. Collins AT, Berry PA, Hyde C i wsp. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
20. Eramo A, Lotti F, Sette G i wsp. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-14.
21. Hermann PC, Huber SL, Herrler i wsp. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
22. Singh SK, Hawkins C, Clarke ID i wsp. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
23. Suetsugu A, Nagaki M, Aoki H i wsp. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-4.
24. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT i wsp. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci 2006; 103: 11154-9.
25. Yin S, Li J, Hu C i wsp. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. lnt J Gynecol Cancer 2007; 120: 1444-50.
26. Zhang S, Balch C, Chan MW i wsp. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-20.
27. Klonisch T, Wiechec E, Hombach-Klonisch S i wsp. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 2008; 14: 450-60.
28. Rich JN. Cancer Stem Cells in Radiation Resistance. Cancer Res 2007; 67: 8980-4.
29. Eyler CE, Rich JN. Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis. J Clin Oncol 2008; 26: 2839-45.
30. Hambardzumyan D, Becher OJ, Rosenblum MK i wsp. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-48.
31. Puc J, Keniry M, Li HS i wsp. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005; 7: 193-204.
32. Hombach-Klonisch S, Paranjothy T, Wiechec E i wsp. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp 2008; 56: 165-80.
33. Fan X, Matsui W, Khaki L i wsp. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-52.
34. Wang J, Guo LP, Chen LZ i wsp. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007; 67: 3716-24.
35. Gailani MR, Stähle-Bäckdahl M, Leffell DJ i wsp. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14: 78-81.
36. Taipale J, Chen JK, Cooper MK i wsp. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406: 1005-9.
37. Berman DM, Karhadkar SS, Hallahan AR i wsp. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297: 1559-61.
38. Watkins DN, Berman DM, Burkholder SG i wsp. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422: 313-7.
39. Francipane MG, Alea MP, Lombardo i wsp. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 2008; 68: 4022-5.
40. Massard C, Teutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006; 17: 1620-4.
41. Jin L, Hope KJ, Zhai Q i wsp. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Natural Medicine 2006; 12: 1167-1174.
42. Lee J, Son MJ, Woolard K i wsp. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008; 13: 69-80.
43. Bourguignon LY, Peyrollier K, Xia W i wsp. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008; 283: 17635-51.
44. Dylla SJ, Beviglia L, Park IK i wsp. Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy. PLoS ONE. 2008; 18; 3: e2428
45. Beier D, Röhrl S, Pillai DR i wsp. Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma. Cancer Res 2008; 68: 5706-15.
46. Liu G, Yuan X, Zeng Z i wsp. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 2; 5:67.
47. Yilmaz OH, Valdez R, Theisen BK i wsp. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-82.
48. Kawasaki BT, Farrar WL Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007; 364: 778-82
49. Halama N, Zoernig I, Jäger D. Immunotherapy for cancer - modern immunologic strategies in oncology. Dtsch Med Wochenschr 2008; 133: 2105-8.
50. Duan W, Ding H, Subler MA i wsp. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice. Oncogene 2002; 21: 7831-8.
51. Chen L, Shen R, Ye Y i wsp. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE. 2007; 3: 1-16.
52. Spisek R, Kukreja A, Chen LC i wsp. Frequent and specificimmunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204: 831-40.
53. Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C i wsp. Nat Neurosci 2006; 9: 331-9.
54. Shen Q, Goderie SK, Jin L i wsp. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004; 304: 1338-40.
55. Yang ZJ, Wechsler-Reya RJ. Hit 'Em Where They Live: Targeting the Cancer Stem Cell Niche. Cancer Cell 2007; 11: 3-5.
56. Calabrese C, Poppleton H, Kocak M i wsp. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
57. Vredenburgh JJ, Desjardins A, Herndon JE i wsp. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-9.
58. Bao Wu Q, Sathornsumetee S i wsp. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-8.
59. Malecki M, Jastrzȩbski Z, Przybyszewska M i wsp. Antiangiogenic gene therapy: application of soluble FLT-1 receptor. Adv Clin Exp Med 2004; 13: 227-33
60. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Natural Medicine 2001; 7: 987-9.
61. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 2004; 6: 529-31.
62. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-35.
63. Folkins C, Man S, Xu P i wsp. Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors. Cancer Res 2007; 67: 3560-4.
64. Lee CG, Heijn M, di Tomaso E i wsp. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565-70.
65. Hess C, Vuong V, Hegyi I i wsp. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelialcells and tumour growth. Br J Cancer 2001; 85: 2010-16.
66. Li J, Huang S, Armstrong EA i wsp. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 [VEGFR2] blockade, lnt J Radiat Oncol Biol Phys 2005; 62: 1477-85.
67. Zhang X, Komaki R, Wang L i wsp. Treatment of Radioresistant Stem-Like Esophageal Cancer Cell by an Apoptotic Gene-Armed, Telomerase-Specific Oncolytic Adenovirus. Clin Cancer Res 2008; 14: 2813-23.
68. Yin C, Lin Y, Zhang X i wsp. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 2008; 48: 1528-1539
69. Andreas G. Schätzlein. Delivering cancer stem cell therapies - A role for nanomedicines? Eur J Cancer 2006; 42: 1309-15.
70. Minko T, Kopeckova P, Pozharov V i wsp. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 1998; 54: 223-33.
71. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60.
72. Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 2003; 91: 75-83.
73. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-79.
74. Venne A, Li S, Mandeville R i wsp. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996; 56: 3626-9.
75. Tokes ZA, Rogers KE, Rembaum A. Synthesis of adriamycin coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci 1982; 79: 2026-30.
76. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000; 85: 217-29.
77. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.